What Happens If You Stop Taking Farxiga?

Talk with your healthcare provider before stopping Farxiga. You may be considering stopping because of cost, side effects, surgery, or changes in your health.

Farxiga (dapagliflozin) is used for more than lowering blood sugar. Depending on your condition, your healthcare provider may prescribe it to help manage type 2 diabetes, reduce the risk of certain heart-failure complications, or slow the progression of chronic kidney disease in eligible adults.

Because Farxiga is used for different conditions, the effects of stopping it depend on why it was prescribed.

Key Takeaways

• Farxiga is not known to cause classic withdrawal syndrome. Stopping it does not typically cause withdrawal symptoms, but you may lose some of the benefits it was providing.
• Stopping Farxiga may make some health conditions less controlled. Depending on why you take it, blood sugar may rise, and you may lose some of the heart or kidney protection associated with ongoing treatment.
• Farxiga generally does not require tapering. It can usually be stopped without gradually lowering the dose, but that does not mean you should stop it without discussing the change with your healthcare provider
• Temporary interruption may sometimes be necessary. Farxiga may need to be paused before major surgery or procedures involving prolonged fasting, and during certain illnesses or other situations that increase the risk of ketoacidosis. The U.S. regulators’ prescribing information recommends withholding Farxiga for at least 3 days before major surgery or procedures associated with prolonged fasting, when possible.
• Some symptoms require urgent medical attention. Nausea, vomiting, stomach pain, unusual tiredness, trouble breathing, or confusion may indicate diabetic ketoacidosis (DKA). Severe allergic-reaction symptoms also require urgent care.
• If cost is making Farxiga difficult to afford, discuss your options before missing doses. Your healthcare provider or pharmacist may be able to help you explore ways to continue treatment or identify an appropriate alternative.

How Farxiga Works

Farxiga belongs to a group of medications called SGLT2 inhibitors. It blocks SGLT2 in the kidneys, allowing more glucose and sodium to leave the body through urine. This helps lower blood sugar and contributes to heart and kidney benefits for eligible adults while treatment continues.

Farxiga can help lower blood sugar in people with type 2 diabetes. It is also used for certain adults with heart failure and chronic kidney disease because its effects on glucose and sodium handling may provide heart and kidney benefits while treatment continues.

What Could Change After You Stop Taking Farxiga?

The effects of stopping Farxiga depend mainly on why you take it. Changes may differ for people taking it for type 2 diabetes, heart failure, or chronic kidney disease.

If You’re Taking Farxiga for Type 2 Diabetes

Farxiga helps lower blood sugar in people with type 2 diabetes by increasing the amount of glucose that leaves the body through urine. If you stop taking it, this glucose-lowering effect will no longer be maintained, and your blood sugar may rise.

You may also notice symptoms of high blood sugar, such as increased thirst or urination, if your blood glucose becomes less controlled. Whether these changes occur, and how significant they are, depends on your overall diabetes treatment, including other medications, food intake, physical activity, and how well your diabetes was controlled before stopping Farxiga

If your blood sugar rises after stopping Farxiga, your healthcare provider may need to adjust your treatment plan or recommend another medication.

Stopping or missing a dose of Farxiga does not mean that long-term diabetes complications will occur immediately. The greater concern is persistently high blood sugar over time, which can increase the risk of diabetes-related complications. If you are considering stopping Farxiga, talk with your healthcare provider about how to monitor your blood sugar and whether your treatment plan needs to be changed.

If You’re Taking Farxiga for Heart Failure

If you stop taking Farxiga, you may no longer receive the heart-failure benefits associated with continued Farxiga treatment.

Depending on your condition and other treatments, symptoms of heart failure may worsen or become harder to manage.

You may notice:

• Increasing shortness of breath, especially during activity or when lying down
• New or worsening swelling in your legs, ankles, or feet
• Rapid weight gain, particularly when accompanied by new or worsening swelling or increasing shortness of breath
• Reduced exercise tolerance, such as becoming tired or short of breath with activities that were previously easier
• Increasing fatigue or tiredness

These changes can occur when heart failure becomes less controlled or when fluid builds up in the body. However, not everyone will experience these symptoms after stopping Farxiga, and these symptoms can have other causes.

In clinical trials, people taking Farxiga had fewer heart-failure hospitalizations and, in some studies, fewer cardiovascular deaths than people taking placebo. For example, in the DAPA-HF study, Farxiga reduced the risk of the combined outcome of cardiovascular death, heart-failure hospitalization, or an urgent heart-failure visit. The cardiovascular death component was also lower with Farxiga in that study. These are population-level treatment outcomes and should not be interpreted as a prediction that an individual who stops Farxiga will be hospitalized or die.

If these symptoms develop or worsen after stopping Farxiga, contact your healthcare provider to determine whether your heart failure treatment needs adjustment.

If You’re Taking Farxiga for Chronic Kidney Disease

Farxiga is used in certain adults with chronic kidney disease who are at risk of progression. In clinical trials, ongoing treatment with Farxiga reduced the risk of sustained kidney function decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure compared with placebo

These benefits were demonstrated while participants were receiving treatment in clinical trials. The trials were designed to evaluate the effects of dapagliflozin compared with placebo during the study period, rather than to determine exactly what happens to kidney protection after someone stops taking the medication.

If Farxiga is stopped, you should not assume that the reduction in the risk of kidney disease progression seen during treatment will continue unchanged. This does not mean that your kidney function will immediately decline or that stopping Farxiga will inevitably cause kidney damage. The effect of stopping treatment can vary depending on your underlying kidney disease, other medications, and overall health.

Your healthcare provider can determine whether another treatment or monitoring is needed after stopping Farxiga.

What About Blood Pressure and Weight?

Farxiga may also have modest effects on body weight and blood pressure while you are taking it. These effects may partly result from the increased loss of glucose and sodium through urine.

After stopping Farxiga, some of these effects may lessen over time, but this does not mean everyone will experience weight gain, higher blood pressure, or buildup of excess fluid in the body. Changes in weight can be affected by glucose loss, calorie balance, fluid balance, other medications, diet, physical activity, and overall health. The changes you experience will depend on why you take Farxiga and your overall treatment plan.

Lifestyle Measures That May Support Your Treatment

Lifestyle measures can support your overall health and may help manage conditions such as type 2 diabetes, heart failure, or chronic kidney disease. However, they generally should not be considered direct substitutes for Farxiga or other prescribed heart- or kidney-protective medications. The U.S. regulators describe Farxiga as an adjunct to diet and exercise for blood sugar control and also approve it for certain heart failure and chronic kidney disease benefits.

Depending on your condition and your healthcare provider’s recommendations, lifestyle measures may include:

• Following your clinician-approved eating plan, including any recommendations for carbohydrates, sodium, or other dietary changes.
• Being physically active as appropriate for your condition and fitness level. Your healthcare provider can help determine what type and amount of activity is safe for you.
• Monitoring your weight or blood sugar when advised. Changes in weight or blood sugar may provide useful information about how well your condition is being managed.
• Avoid smoking, which can reduce additional risks to your heart and overall health.
• Follow fluid or sodium instructions if you have heart failure. Your healthcare provider may recommend specific limits based on your symptoms, kidney function, and other treatments.

Does Farxiga Cause Withdrawal, and Can You Stop It Suddenly?

Farxiga is not generally associated with a classic withdrawal syndrome and usually does not require tapering before stopping. However, stopping may reduce the treatment benefits it was providing, and the condition it was prescribed to manage may become less controlled.

Whether Farxiga should be stopped depends on why you take it, your other treatments, and your overall health. Your healthcare provider can determine whether you need another treatment, closer monitoring, or a temporary pause.

What Is Diabetic Ketoacidosis (DKA)?

DKA is a serious condition that occurs when the body does not have enough insulin and begins breaking down fat, causing ketones to build up in the blood. Farxiga-associated DKA can occur even when blood sugar is not extremely high. Symptoms may include nausea, vomiting, stomach pain, unusual tiredness, trouble breathing, or confusion. Seek emergency medical care if these symptoms occur.

When Might Stopping Farxiga Become Part of Your Treatment Plan?

Farxiga may sometimes need to be temporarily paused or stopped for a specific reason. The timing depends on your health and why the medication is being changed.

Surgery or prolonged fasting

Farxiga may need to be temporarily stopped before major surgery or procedures associated with prolonged fasting. The U.S. regulators’ prescribing information recommends withholding Farxiga for at least 3 days before major surgery or procedures associated with prolonged fasting, when possible.

When to Have a Planned Discussion With Your Healthcare Provider

Cost concerns

If the cost of Farxiga is making you consider missing doses or stopping treatment, contact your prescriber before your current supply runs out. Your prescriber or pharmacist can help you explore insurance coverage, assistance programs, or appropriate lower-cost alternatives.

Pregnancy or pregnancy planning

Tell your healthcare provider promptly if you become pregnant while taking Farxiga or if you are planning to become pregnant. Farxiga is not recommended during the second and third trimesters of pregnancy because of concerns about potential effects on the developing kidneys. Do not stop Farxiga or leave diabetes or another condition untreated on your own. Your healthcare provider can weigh the benefits of managing your condition against potential risks to the fetus and determine whether Farxiga should be stopped, changed, or replaced with another treatment. If you are breastfeeding or planning to breastfeed, discuss this with your healthcare provider because breastfeeding guidance may also affect your treatment plan.

Manageable side effects or wanting to change treatment

If side effects are bothersome but not an emergency, discuss treatment options with your healthcare provider

For planned treatment changes, your healthcare provider can help determine whether Farxiga should be continued, temporarily paused, stopped, or replaced with another treatment.

Creating a Safe Plan for Stopping Farxiga

If you and your healthcare provider decide to stop or temporarily pause Farxiga, confirm when to take your last dose, whether another treatment is needed, what to monitor, and when to restart it if the interruption is temporary.

Confirm the Final Dose Date

Ask your healthcare provider when you should take your last dose of Farxiga. The timing depends on why the medication is being paused or stopped. If Farxiga is being paused for surgery or another procedure, confirm the timing with your surgical or prescribing team

Ask Whether Another Medication or Treatment Change Starts Immediately

Stopping Farxiga does not necessarily mean replacing only its blood-sugar-lowering effect. Depending on why it was prescribed, your treatment plan may need to continue addressing blood sugar, heart failure, kidney protection, or fluid management. Your healthcare provider can determine whether another medication, a dose adjustment, or more than one treatment is needed. Do not independently start, stop, or change another medication.

Identify What to Monitor Based on Why You Take Farxiga

The monitoring plan after stopping or temporarily pausing Farxiga depends on the condition it was prescribed to treat. Your healthcare provider should determine which measurements, symptoms, and follow-up tests are appropriate for you.

Why Farxiga was prescribed	What may need monitoring
Type 2 diabetes	Home blood glucose, symptoms of high blood sugar, and the timing of your next A1C or other diabetes follow-up
Heart failure	Body weight, swelling, shortness of breath, fatigue, and blood pressure
Chronic kidney disease	Kidney function, electrolytes, blood pressure, and whether another treatment is needed
Temporary surgical hold	Food and fluid intake, hydration, symptoms that may suggest ketoacidosis, and criteria for safely restarting Farxiga

Confirm Follow-Up Tests or Appointments

Ask whether you need blood or urine tests or a follow-up appointment after stopping or changing Farxiga. The timing and type of monitoring should be based on your individual health needs.

If the Interruption Is Temporary, Confirm When to Restart

If Farxiga is being paused rather than permanently discontinued, ask your healthcare provider exactly when it should be restarted and what conditions need to be met first.

After surgery or prolonged fasting, your healthcare team should confirm that you are clinically stable and have resumed normal eating and drinking before restarting Farxiga.

Exploring Your Options Before Stopping Farxiga

If Farxiga is no longer appropriate or affordable, your healthcare provider can review other treatment options based on your condition and treatment goals

What You Can Consider Before Stopping Farxiga Completely

Farxiga belongs to a group of medications called SGLT2 inhibitors. Other SGLT2 inhibitors, such as Jardiance and Invokana, may be appropriate for some people depending on their medical condition, kidney function, other medications, insurance coverage, and treatment goals.

If your prescriber determines that another SGLT2 inhibitor is appropriate for you, compare the total cost of the exact prescribed strength and dosing regimen rather than comparing prices for different strengths or quantities. Do not switch from Farxiga to another medication based on price alone. Your prescriber should determine whether the alternative provides appropriate treatment for your specific condition.

If Farxiga is not the right choice for you, your healthcare provider may consider other treatments based on the specific goal that needs to be addressed.

These medications are not interchangeable with Farxiga and may not provide all of the same benefits.

• Blood-sugar management: Other glucose-lowering medicines may be considered when blood sugar control is the main treatment goal.
• Heart-failure management: Other guideline-directed therapies may be used to manage heart failure and reduce the risk of related complications.
• Kidney protection and blood pressure management: Appropriate renin-angiotensin system therapies and other treatments may be used when kidney protection or blood pressure management is a treatment goal.
• Managing excess fluid: Diuretics may be prescribed when fluid buildup needs to be controlled.

The appropriate treatment depends on your condition, kidney function, other medications, and treatment goals. One treatment should not be assumed to replace every benefit Farxiga was providing

Understanding Your Insurance Costs Before Making a Treatment Change

Your out-of-pocket cost for Farxiga can depend on your insurance plan, deductible, copay or coinsurance, and the medication’s formulary tier.

If Farxiga is expensive under your current plan, ask your insurance company, pharmacist, or healthcare provider whether a formulary exception, coverage review, assistance program, or appropriate lower-cost alternative may be available.

Explore Savings Programs and Assistance Options That May Help Lower Costs

If the cost of Farxiga is difficult to manage, you may qualify for manufacturer savings programs, patient assistance programs, or other support options, depending on your insurance status and eligibility. Before stopping Farxiga because of cost, discuss these options with your healthcare provider or pharmacist.

Considering DoctorSolve for Cash-Pay Options

If you are considering DoctorSolve as a cash-pay option, review the current price for the exact medication, strength, dosage form, and quantity prescribed. The final cost may also depend on shipping, dispensing fees, taxes, product availability, and the dispensing pharmacy.

What to Confirm Before Ordering From DoctorSolve

Before completing an order, customers should confirm the dispensing pharmacy, product source, pharmacist-support options, and total delivered cost.

• Confirm that a valid prescription is required for the medication.
• Confirm which pharmacy will dispense the prescription and where it is licensed.
• Confirm that the medication name, strength, dosage form, and quantity match the prescription.
• Confirm how to contact the dispensing pharmacy or obtain pharmacist support for medication-related questions.
• Confirm the total delivered cost, including shipping, dispensing fees, taxes, and other applicable charges.

These details provide a more practical basis for evaluating an online pharmacy service than relying only on general descriptions such as “safe” or “trusted.”

Pricing Details for This Example

The prices were checked on August 21, 2026, and are shown in U.S. dollars. Both listings are for brand-name Farxiga (dapagliflozin) 5 mg oral tablets. The GoodRx example is a cash-price listing for 30 tablets, while the DoctorSolve example is a listing for 84 tablets. Because the quantities differ, the GoodRx price was scaled to an 84-tablet supply for comparison. The DoctorSolve price includes a dispensing fee, medical review fee, and packing fee.

Using the GoodRx cash-price example of $288 for 30 tablets, and assuming one tablet daily, the estimated cost for 84 tablets is $806.40 ($288 ÷ 30 × 84). At one 5 mg tablet daily, 84 tablets provide 84 days of treatment. Therefore, 365 ÷ 84 is approximately 4.35 packages per year. The estimated medication-only annual cost is $806.40 × (365 ÷ 84) = approximately $3,503.

Using the DoctorSolve price of $244 for 84 tablets, and assuming one tablet daily, the estimated medication-only annual cost is $244 × (365 ÷ 84) = approximately $1,060. The difference between the two examples is approximately $2,443 per year.

The DoctorSolve example works out to approximately $2.90 per 5 mg tablet based on $244 for 84 tablets.

The GoodRx price is a cash-price estimate rather than an insurance-negotiated price. It reflects the price displayed by GoodRx for the specified Farxiga prescription and may vary by pharmacy, location, prescription details, discounts, and time. Insurance coverage is not included in this cash-price example. The price was available when checked on August 21, 2026.

The DoctorSolve price may also change based on product availability and ordering details. The DoctorSolve listing shown includes a dispensing fee, medical review fee, and packing fee; other applicable charges, such as shipping or taxes, may affect the final delivered cost. Confirm the final cost before ordering.

Price disclaimer: Prices were checked on August 21, 2026, and are shown in U.S. dollars. The annual figures are estimated costs based on one 5 mg tablet daily. The GoodRx annual estimate is based on its listed price of $288 for 30 tablets and is scaled to an 84-tablet supply for comparison. Prices, product availability, dispensing pharmacy, shipping charges, taxes, and other costs can change. This comparison is provided for general reference only and does not guarantee a particular price, availability, or savings amount.

What Changes After Stopping Farxiga Should You Discuss With Your Doctor?

After stopping Farxiga, some changes may require emergency medical care, while others should be discussed promptly with your healthcare provider or addressed during a routine follow-up. Knowing the difference can help you respond appropriately.

Seek Emergency Care Now

Seek emergency medical care if you develop symptoms that may indicate a serious or life-threatening condition, including:

Possible diabetic ketoacidosis (DKA)

Nausea, vomiting, stomach pain, unusual tiredness, trouble breathing, or confusion can be signs of DKA. DKA can occur even when blood sugar is not extremely high. Seek emergency medical care if these symptoms occur.

Possible Fournier’s gangrene

Severe pain or tenderness, redness, or swelling around the genitals or the area between the genitals and anus, particularly when accompanied by fever or feeling unusually unwell, requires urgent medical evaluation. This rare infection can become life-threatening.

Severe allergic reaction

Swelling of the face, lips, tongue, or throat, or severe trouble breathing or swallowing, requires emergency medical attention.

Contact Your Healthcare Provider Promptly

Contact your healthcare provider promptly if you notice changes that are not an emergency but may indicate that your treatment plan needs adjustment, including:

• Blood sugar levels that are consistently higher than your usual range after stopping Farxiga. Your healthcare provider can determine whether your treatment needs adjustment.
• Rapid weight gain, particularly with new or worsening swelling or increasing shortness of breath, which may indicate fluid retention in people with heart failure.
• New or worsening shortness of breath or fatigue, particularly if these symptoms occur with other heart-failure symptoms.
• New or worsening swelling in the legs, ankles, or feet, particularly with weight gain or increasing shortness of breath.
• Persistent or concerning urinary symptoms, such as painful urination, frequent or urgent urination, lower abdominal or back pain, fever, or chills.

Schedule Routine Follow-Up

Schedule a follow-up with your healthcare provider after stopping Farxiga to review your symptoms, medications, and treatment plan, even if you feel well.

Depending on why you take Farxiga, your provider may review:

• Blood sugar control if you take Farxiga for type 2 diabetes.
• Weight, swelling, blood pressure, and heart-failure symptoms if you take Farxiga for heart failure.
• Kidney function and other appropriate laboratory tests if you take Farxiga for chronic kidney disease.
• Your overall treatment plan, including whether another treatment is needed.

What to Remember Before Stopping Farxiga

Farxiga usually does not require tapering, but stopping may reduce its treatment benefits. Follow your healthcare provider’s plan for stopping or temporarily pausing treatment. Seek emergency care for symptoms of DKA or another serious medical emergency.

Frequently Asked Questions (FAQs)

Can you just quit taking Farxiga?

Farxiga usually does not require tapering, but stopping may affect the condition it was prescribed to manage. Your healthcare provider can determine whether you need another treatment or monitoring after stopping.

Why are doctors pushing Farxiga?

Farxiga may be recommended because it can provide different benefits depending on why it is prescribed, including blood-sugar control, heart-failure treatment, or chronic kidney disease management. Ask your doctor which benefit is expected in your case.

What is the downside of Farxiga?

Farxiga can cause side effects such as genital yeast infections, urinary tract infections, increased urination, dehydration, and low blood pressure. Less common but serious risks include DKA and Fournier’s gangrene.

Can you skip a day of Farxiga?

If you miss a dose, take it when you remember unless it is almost time for your next dose. If it is almost time, skip the missed dose and return to your regular schedule. Do not take two doses at once.

What organ is Farxiga hard on?

Farxiga acts on the kidneys by blocking SGLT2 and increasing glucose and sodium excretion in urine. It can cause a small early decrease in eGFR after treatment begins, which does not necessarily indicate kidney damage. For eligible adults with chronic kidney disease, Farxiga can also provide kidney-protective benefits.

References

1. American Society of Health-System Pharmacists. (2020). Dapagliflozin. MedlinePlus. https://medlineplus.gov/druginfo/meds/a614015.html
2. Ali, A. E., Mazroua, M. S., ElSaban, M., Najam, N., Kothari, A. S., Mansoor, T., Amal, T., Lee, J., & Kashyap, R. (2023). Effect of dapagliflozin in patients with heart failure: A systematic review and meta-analysis. Global Heart, 18(1), Article 45. https://doi.org/10.5334/gh.1258
3. Beernink, J. M., Jongs, N., Mosterd, C. M., Scholtes, R. A., Caldwell‐McGee, A., Casillas, D., Driscoll, L., Greasley, P. J., Karlsson, C., Hammarstedt, A., Sridhar, V. S., Muskiet, M. H. A., Laverman, G. D., Cherney, D. Z. I., Bjornstad, P., van Raalte, D. H., & Heerspink, H. J. L. (2025). Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial. Diabetes, Obesity and Metabolism. https://pmc.ncbi.nlm.nih.gov/articles/PMC12232338/
4. Blair, H. A. (2021). Dapagliflozin: A review in symptomatic heart failure with reduced ejection fraction. American Journal of Cardiovascular Drugs, 21(6), 701–710. https://doi.org/10.1007/s40256-021-00503-8
5. Cerner Multum. (2023a). Farxiga. Drugs.com. https://www.drugs.com/farxiga.html
6. Cerner Multum. (2023b). Farxiga patient tips. Drugs.com. https://www.drugs.com/tips/farxiga-patient-tips
7. Chertow, G. M., Correa‐Rotter, R., Vart, P., Jongs, N., McMurray, J. J. V., Rossing, P., Langkilde, A. M., Sjöström, C. D., Toto, R. D., Wheeler, D. C., & Heerspink, H. J. L. (2023). Effects of dapagliflozin in chronic kidney disease, with and without other cardiovascular medications: DAPA‐CKD trial. Journal of the American Heart Association, 12(10), Article e028739. https://doi.org/10.1161/JAHA.122.028739
8. Dhillon, S. (2019). Dapagliflozin: A review in type 2 diabetes. Drugs, 79(10), 1135–1146. https://doi.org/10.1007/s40265-019-01148-3
9. Drugs.com. (2023b). What happens if you suddenly stop taking diabetes medication? https://www.drugs.com/medical-answers/you-stop-taking-diabetes-medication-3565614/
10. Drugs.com. (2024). Does Farxiga cause kidney damage? https://www.drugs.com/medical-answers/farxiga-kidney-damage-3540664/
11. Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F. F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., Sjöström, C. D., Toto, R. D., Langkilde, A. M., & Wheeler, D. C. (2020). Dapagliflozin in patients with chronic kidney disease. The New England Journal of Medicine, 383(15), 1436–1446. https://doi.org/10.1056/NEJMoa2024816
12. Kasichayanula, S., Liu, X., Lacreta, F., Griffen, S. C., & Boulton, D. W. (2014). Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter-2. Clinical Pharmacokinetics, 53(1), 17–27. https://doi.org/10.1007/s40262-013-0104-3
13. National Institute on Aging. (2023). Discussing health decisions with your doctor. U.S. Department of Health and Human Services. https://www.nia.nih.gov/health/medical-care-and-appointments/discussing-health-decisions-your-doctor
14. National Library of Medicine. (2018). StatPearls: Renal physiology. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK507713/
15. National Library of Medicine. (2019a). StatPearls: SGLT2 inhibitors. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK538730/
16. National Library of Medicine. (2019b). StatPearls: Type 2 diabetes. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK534848/
17. National Library of Medicine. (2020a). StatPearls: Diabetic ketoacidosis. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK55446/
18. National Library of Medicine. (2020b). StatPearls: Diabetes management. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK279506/
19. National Library of Medicine. (2020c). StatPearls: Hyperglycemia. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK279114/
20. National Library of Medicine. (2021a). StatPearls: Dapagliflozin. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK576405/
21. National Library of Medicine. (2021b). StatPearls: Chronic kidney disease. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK572291/
22. National Library of Medicine. (2022). StatPearls: Heart failure with reduced ejection fraction. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK580680/
23. National Library of Medicine. (2024). StatPearls: Heart failure guidelines. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK603647/
24. PubMed Central. (2010). PMC2905667. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC2905667/
25. PubMed Central. (2011). PMC3119470. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC3119470/
26. PubMed Central. (2014a). PMC3906841. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC3906841/
27. PubMed Central. (2014b). PMC4132377. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC4132377/
28. PubMed Central. (2015a). PMC4619996. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC4619996/
29. PubMed Central. (2015b). PMC4675553. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC4675553/
30. PubMed Central. (2018a). PMC5764786. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC5764786/
31. PubMed Central. (2018b). PMC5836959. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC5836959/
32. PubMed Central. (2018c). PMC6023663. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC6023663/
33. PubMed Central. (2019a). PMC6342665. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC6342665/
34. PubMed Central. (2019b). PMC6825492. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC6825492/
35. PubMed Central. (2019c). PMC6881422. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC6881422/
36. PubMed Central. (2020). PMC6005223. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC6005223/
37. PubMed Central. (2021a). PMC8317009. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC8317009/
38. PubMed Central. (2021b). PMC8320012. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC8320012/
39. PubMed Central. (2021c). PMC8356825. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC8356825/
40. PubMed Central. (2021d). PMC8409884. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC8409884/
41. PubMed Central. (2022a). PMC9263228. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC9263228/
42. PubMed Central. (2022b). PMC9309138. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC9309138/
43. PubMed Central. (2022c). PMC9560052. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC9560052/
44. PubMed Central. (2022d). PMC9727535. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC9727535/
45. PubMed Central. (2023a). PMC10154648. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC10154648/
46. PubMed Central. (2023b). PMC10387929. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC10387929/
47. PubMed Central. (2023c). PMC10400285. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC10400285/
48. PubMed Central. (2024a). PMC10838136. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC10838136/
49. PubMed Central. (2024b). PMC11089680. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC11089680/
50. PubMed Central. (2024c). PMC11172815. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC11172815/
51. PubMed Central. (2024d). PMC11546491. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC11546491/
52. PubMed Central. (2025). PMC11947582. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC11947582/
53. PubMed. (2010). PMID: 20508640. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/20508640/
54. PubMed. (2016). PMID: 27461213. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/27461213/
55. PubMed. (2024a). PMID: 38666776. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/38666776/
56. PubMed. (2024b). PMID: 38730538. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/38730538/
57. U.S. Food and Drug Administration. (2020). Farxiga (dapagliflozin) prescribing information (NDA 202293/S-020). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202293s020lbl.pdf
58. U.S. Food and Drug Administration. (2023). Farxiga approval summary and clinical review (NDA 202293/S-026). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/202293Orig1s026.pdf
59. U.S. Food and Drug Administration. (2024). FDA approves first generic dapagliflozin tablets. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-approves-first-generic-dapagliflozin-tablets
60. U.S. Food and Drug Administration. (2026). Farxiga (dapagliflozin) prescribing information (NDA 202293/S-035). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/202293s035lbl.pdf
61. WebMD. (2023a). Farxiga oral: Uses, side effects, interactions, and pictures. https://www.webmd.com/drugs/farxiga-dapagliflozin#interactions
62. WebMD. (2023b). Farxiga and type 2 diabetes. https://www.webmd.com/diabetes/farxiga-diabetes
63. Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Secemsky, E. A., Bansilal, S., Mazer, B. D., Oude Ophuis, A. J., Yanuv, I., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Gause-Nilsson, I. A. M., Donnelly, N. A., Langkilde, A. M., & Sabatine, M. S. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine, 380(4), 347–357. https://pubmed.ncbi.nlm.nih.gov/30415602/
64. Health Canada. (2021, June 10). Choosing a safe online pharmacy. Government of Canada. https://www.canada.ca/en/health-canada/topics/buying-using-drug-health-products-safely/safe-use-online-pharmacies.html
65. Gordon, J., Danne, T., Beresford-Hulme, L., Bennet, H., Tank, A., Edmonds, C., Thorén, F., Scheerer, M. F., & McEwan, P. (2020). Adverse changes in HbA1c, body weight and insulin use in people with type 1 diabetes mellitus following dapagliflozin discontinuation in the DEPICT clinical trial programme. Diabetes Therapy, 11(5), 1135–1146. https://doi.org/10.1007/s13300-020-00807-z
66. National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). The A1C test & diabetes. U.S. Department of Health and Human Services, National Institutes of Health. https://www.niddk.nih.gov/health-information/diagnostic-tests/a1c-test
67. American Diabetes Association Professional Practice Committee. (2025). 11. Chronic kidney disease and risk management: Standards of care in diabetes—2025. Diabetes Care, 48(1 Suppl 1), S239–S251. https://doi.org/10.2337/dc25-S011
68. Martínez-Montoro, J. I., Picón-César, M. J., Simón-Frapolli, V. J., Pinzón-Martín, J. L., García-Alemán, J., Durán-Martínez, M., & Tinahones, F. J. (2023). Evaluation of the clinical impact of dapagliflozin discontinuation as adjunctive therapy for patients with type 1 diabetes after indication withdrawal: A two-center retrospective study. Diabetes Care, 46(5), e101–e102. https://doi.org/10.2337/dc23-0083
69. González-Clemente, J. M., García-Castillo, M., Gorgojo-Martínez, J. J., Llorente Gómez-Segura, I., Jiménez-Buiza, A., Matute-Troncoso, E., Tejera-Pérez, C., Izarra-Navarro, A., & Lecube-Torelló, A. (2022). Beyond the glycaemic control of dapagliflozin: Impact on arterial stiffness and macroangiopathy. Diabetes Therapy, 13(7), 1281–1298. https://doi.org/10.1007/s13300-022-01280-6
70. Cleveland Clinic. (n.d.). Dapagliflozin tablets. Cleveland Clinic. https://my.clevelandclinic.org/health/drugs/19382-dapagliflozin-tablets
71. Mayo Clinic. (n.d.). Dapagliflozin (oral route): Description and brand names. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/dapagliflozin-oral-route/description/drg-20095101
72. Chen, L., LaRocque, L., Efe, O., Wang, J., Sands, J. M., & Klein, J. D. (2016). Effect of dapagliflozin treatment on fluid and electrolyte balance in diabetic rats. The American Journal of the Medical Sciences, 352(5), 517–523. https://doi.org/10.1016/j.amjms.2016.08.015
73. Plosker, G. L. (2014). Dapagliflozin: A review of its use in patients with type 2 diabetes. Drugs, 74(18), 2191–2209. https://doi.org/10.1007/s40265-014-0324-3
74. WebMD. (n.d.). Control your blood sugars. WebMD. https://www.webmd.com/diabetes/ss/slideshow-control-your-blood-sugars
75. Asif, M. (2014). The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. Journal of Education and Health Promotion, 3, 1. https://doi.org/10.4103/2277-9531.127541
76. Tomic, D., Shaw, J. E., & Magliano, D. J. (2022). The burden and risks of emerging complications of diabetes mellitus. Nature Reviews Endocrinology, 18(9), 525–539. https://doi.org/10.1038/s41574-022-00690-7
77. National Heart, Lung, and Blood Institute. (n.d.). Heart failure: Symptoms. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health/heart-failure/symptoms
78. Bailey, C. J., Day, C., & Bellary, S. (2022). Renal protection with SGLT2 inhibitors: Effects in acute and chronic kidney disease. Current Diabetes Reports, 22(1), 39–52. https://doi.org/10.1007/s11892-021-01442-z
79. National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Preventing chronic kidney disease. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/prevention
80. Neale, E. P., Do Rosario, V., Probst, Y., Beck, E., Tran, T. B., & Lambert, K. (2023). Lifestyle interventions, kidney disease progression, and quality of life: A systematic review and meta-analysis. Kidney Medicine, 5(6), 100643. https://doi.org/10.1016/j.xkme.2023.100643
81. DailyMed. (2026). FARXIGA—dapagliflozin tablet, film coated. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef9e9c8c-5460-4193-952a-0c249dd071bd
82. Rippe, J. M. (2018). Lifestyle medicine: The health promoting power of daily habits and practices. American Journal of Lifestyle Medicine, 12(6), 499–512. https://doi.org/10.1177/1559827618785554
83. National Center for Biotechnology Information. (n.d.). NBK538730. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK538730/
84. Mayo Clinic. (n.d.). Heart failure: Symptoms and causes. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/heart-failure/symptoms-causes/syc-20373142
85. Dalton, K., & Byrne, S. (2017). Role of the pharmacist in reducing healthcare costs: Current insights. Integrated Pharmacy Research and Practice, 6, 37–46. https://doi.org/10.2147/IPRP.S108047
86. DailyMed. (2026). FARXIGA—dapagliflozin tablet, film coated. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f90c94-71cb-4a1f-81ff-8004b850529b
87. National Center for Biotechnology Information. (n.d.). NBK52684. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK52684/
88. Leibowitz, K. A., Howe, L. C., & Crum, A. J. (2021). Changing mindsets about side effects. BMJ Open, 11(2), e040134. https://doi.org/10.1136/bmjopen-2020-040134
89. Nashar, K., & Khalil, P. (2022). Clinical evaluation of dapagliflozin in the management of CKD: Focus on patient selection and clinical perspectives. International Journal of Nephrology and Renovascular Disease, 15, 289–308. https://doi.org/10.2147/IJNRD.S234282
90. Gorgojo-Martínez, J. J., Górriz, J. L., Cebrián-Cuenca, A., Castro Conde, A., & Velasco Arribas, M. (2024). Clinical recommendations for managing genitourinary adverse effects in patients treated with SGLT-2 inhibitors: A multidisciplinary expert consensus. Journal of Clinical Medicine, 13(21), 6509. https://doi.org/10.3390/jcm13216509
91. National Center for Biotechnology Information. (n.d.). NBK603647. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK603647/
92. National Center for Biotechnology Information. (n.d.). NBK436014. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK436014/
93. Isaza, N., Calvachi, P., Raber, I., Liu, C.-L., Bellows, B. K., Hernandez, I., Shen, C., Gavin, M. C., Garan, A. R., & Kazi, D. S. (2021). Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction. JAMA Network Open, 4(7), e2114501. https://doi.org/10.1001/jamanetworkopen.2021.14501
94. Health Canada. (2014). Guidance document: Labelling of pharmaceutical drugs for human use. Health Canada. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/labelling-pharmaceutical-drugs-human-use-2014-guidance-document.html
95. Wong, R., Mehta, T., Very, B., Luo, J., et al. (2023). Where do real-time prescription benefit tools fit in the landscape of high US prescription medication costs? A narrative review. Journal of General Internal Medicine, 38(4), 1038–1045. https://doi.org/10.1007/s11606-022-07945-z
96. Mulcahy, A. W., Schwam, D., & Lovejoy, S. L. (2024). International prescription drug price comparisons: Estimates using 2022 data. RAND Health Quarterly, 11(3), 5.
97. Herges, J. R., Neumiller, J. J., & McCoy, R. G. (2021). Easing the financial burden of diabetes management: A guide for patients and primary care clinicians. Clinical Diabetes, 39(4), 427–436. https://doi.org/10.2337/cd21-0004
98. National Center for Biotechnology Information. (n.d.). NBK492989. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK492989/
99. Maxwell, S. R. J. (2016). Rational prescribing: The principles of drug selection. Clinical Medicine, 16(5), 459–464. https://doi.org/10.7861/clinmedicine.16-5-459
100. Hamamoto, H., & Noda, M. (2015). Body weight gain and hyperphagia after administration of SGLT-2 inhibitor: A case report. American Journal of Case Reports, 16, 863–867. https://doi.org/10.12659/AJCR.896233
101. Drugs.com. (n.d.). Missed dose of medication. Drugs.com. https://www.drugs.com/insights/miss-dose-medication-3573157/
102. Boyle, T. A., Morrison, B., & Mahaffey, T. (2022). Media generation and pharmacy regulatory authority awareness. Journal of Pharmacy Practice, 38(1), 39–45. https://doi.org/10.1177/87551225211051593
103. National Institute on Deafness and Other Communication Disorders. (n.d.). NIDCD guidelines for data and safety monitoring in clinical trials. NIDCD. https://www.nidcd.nih.gov/research/clinical-studies/nidcd-guidelines-data-and-safety-monitoring-clinical-trials
104. Kairi, J. K., & Sharma, A. K. (2017). Substitutes of prescription medicines—A review of concerns relevant to doctors and patients. Journal of Clinical and Diagnostic Research, 11(8), FE01–FE05. https://doi.org/10.7860/JCDR/2017/28552.10439
105. Zwisler, J. E., Larsen, J., & Gram, L. F. (2009). When to stop? Scandinavian Journal of Primary Health Care, 27(1), 1–3. https://doi.org/10.1080/02813430902731233
106. Teleanu, I. C., Bejan, G. C., Poiană, I. R., Mîrșu-Păun, A., & Dumitrescu, S. I. (2025). Remote monitoring of patients with heart failure: Characteristics of effective programs and implementation strategies. Vascular Health and Risk Management, 21, 489–503. https://doi.org/10.2147/VHRM.S521952
107. Chomiuk, T., Niezgoda, N., Mamcarz, A., & Śliż, D. (2024). Physical activity in metabolic syndrome. Frontiers in Physiology, 15, 1365761. https://doi.org/10.3389/fphys.2024.1365761
108. Morden, A., Horwood, J., Whiting, P., Savovic, J., Tomlinson, L., Blakeman, T., Tomson, C., Richards, A., Stone, T., & Caskey, F. (2015). The risks and benefits of patients temporarily discontinuing medications in the event of an intercurrent illness: A systematic review protocol. Systematic Reviews, 4, 139. https://doi.org/10.1186/s13643-015-0135-y